Biogen Idec Tops Q4 EPS Estimates , Guides 2011 Higher

Описание: Biogen Idec (NASDAQ:BIIB) reported Q4 EPS of $1.42, above the consensus estimate of $1.23. Revenue rose to $1.22 billion, better than the $1.17 billion analysts were expecting.

The company reported Tysabri revenue in the quarter of $242 million (vs. estimate of $239 million) and reported Avonex sales of $654 million (vs. an estimate of $638 million).

Biogen said it sees full-year 2011 EPS above $5.70, vs. a Street forecast of $5.63 per share.

CEO Dr. George Scangos said, "In addition to driving AVONEX and TYSABRI revenue growth, we also substantially reduced our cost base, focused the company, and recruited top talent. We will continue the company's transformation in 2011, and we're looking forward to several key pipeline milestones in the coming months."